Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 3.02
PTC Therapeutics completed a $550 million private placement of convertible senior notes with an initial conversion price of approximately $107.48 per share, sold to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The company does not intend to register the resale of the notes or conversion shares, creating significant dilution potential to common shareholders. Net proceeds of $328.8 million are being used to repurchase $222.0 million in aggregate principal of existing convertible notes and for general corporate purposes.
View raw filing on EDGAR →
8-K
M&A activity
confidence 60%
filed 2026-06-18
Item 2.03
Item 2.03 incorporates Item 1.01 by reference, indicating a material transaction that creates direct financial obligations consistent with M&A activity classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses the full exercise of an over-allotment option on June 18, 2026, resulting in the sale of 116,667 additional shares of common stock at $4.33 per share for net proceeds of approximately $470,858. This represents a dilutive equity issuance that increases the company's share count and is material to investors assessing ownership dilution and capital structure changes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting held on June 17, 2026, covering four proposals: election of six directors, ratification of Grant Thornton LLP as auditor, Say-on-Pay advisory vote, and approval of the Sixth Amended and Restated 2010 Equity Incentive Plan. The filing presents detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures and is material to investors assessing board composition and governance matters.
View raw filing on EDGAR →
8-K
Other material
confidence 71%
filed 2026-06-18
Item 1.01
BrightView extended the maturity of its senior secured term loans from April 2029 to June 2033 (Amendment No. 11 to Credit Agreement) and its receivables financing facility from June 2027 to June 2029 (Sixth Amendment to Receivables Financing Agreement). These refinancings strengthen the company's balance sheet by extending its debt maturity profile and providing additional liquidity runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-18
Item 2.02
This is a press release announcing the Trust's monthly cash distribution of $0.017000 per unit payable July 15, 2026, along with detailed financial and operational metrics including oil/gas sales volumes, realized wellhead prices, cash receipts, and operating expenses. The disclosure includes specific production data (31,005 barrels of oil, 548,911 Mcf of natural gas) and pricing information ($82.93/Bbl oil, $4.74/Mcf gas), which are core financial results for a royalty trust. This is material to unitholders as it directly affects the periodic distributions they receive.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
Epsilon Energy entered into an at-the-market (ATM) sales agreement with Roth Capital Partners authorizing the sale of up to $15 million in common shares. This is a dilutive equity issuance mechanism that allows the company to raise capital through registered offerings at prevailing market prices. The material nature of the $15 million authorization and the equity dilution to existing shareholders makes this a significant capital-raising event that would affect investor assessment of the company's financing strategy and shareholder ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Tidewater held its Annual Meeting of Stockholders on June 16, 2026, with 89.57% attendance. Stockholders approved all four proposals: election of seven directors, advisory vote on executive compensation, amendment to the 2021 Stock Incentive Plan increasing available shares by 2,250,000, and ratification of PricewaterhouseCoopers LLP as auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure presents the complete voting results from BJ's Wholesale Club's annual meeting of shareholders held on June 18, 2026, covering seven distinct proposals: election of ten directors, advisory vote on named executive officer compensation, frequency of future compensation votes, ratification of PricewaterhouseCoopers LLP as independent auditor, and shareholder proposals on majority voting and environmental reporting. The filing explicitly states voting tallies (FOR, AGAINST, WITHHELD, ABSTAINED, BROKER NON-VOTES) for each proposal, which is the core content of a shareholder_vote_results disclosure under Item 5.07.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
EX-99.1
NetClass Technology Inc. has entered into a Technical Development Service Agreement with Bangyuan Liu to issue 2,800,000 ordinary shares as consideration for software development services over a one-year engagement, with issuance required by May 31, 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
EX-99.2
NetClass Technology Inc. has agreed to issue 3,200,000 Class A ordinary shares to Akaewood Investment Holding Co., Ltd. as consideration for AI-based technology R&D services over a 12-month term.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 16, 2026, covering five proposals: director elections (Proposal 1), auditor ratification (Proposal 2), equity plan amendment (Proposal 3), executive compensation advisory vote (Proposal 4), and meeting adjournment (Proposal 5). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures. Director elections and equity plan amendments are material to investors' assessment of governance and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Protagonist Therapeutics held an Annual Meeting of Stockholders at which shareholders voted on four proposals: election of two Class I directors (Dinesh V. Patel and Lewis T. Williams), an advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as the independent auditor, and approval of the 2026 Equity Incentive Plan. Final voting results for all four proposals are disclosed.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
KKR FS Income Trust issued 2,785,366.442 Class I shares for approximately $81.276 million in an unregistered private offering under Section 4(a)(2) and Regulation D to accredited investors, diluting existing shareholder ownership.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
The Company disclosed its net asset value per share of $29.18 as of May 31, 2026 (aggregate NAV of $1.589 billion) and reported that its ongoing private offering has raised $1.748 billion of a $5.0 billion target, providing investors with current valuation and offering progress metrics.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 3.02
Graf Global Corp. issued Class A Ordinary Shares upon conversion of Class B Ordinary Shares, relying on Section 3(a)(9) exemption from Securities Act registration. The Sponsor and three board members irrevocably converted 5,749,999 Class B shares into Class A shares on a one-for-one basis, reducing Class B shares outstanding from 5,750,000 to 1, representing a material change in capital structure and shareholder voting/economic rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
KKR FS Income Trust Select issued 183,883.440 Class I shares for approximately $4.597 million pursuant to a continuous private offering under Section 4(a)(2) and Regulation D to accredited investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Willdan Group held its Annual Meeting of Stockholders on June 17, 2026, with detailed voting results disclosed for all four proposals: director elections, auditor ratification, advisory compensation vote, and amendments to the 2008 Performance Incentive Plan.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-18
Item 5.02
The Board approved and stockholders ratified amendments to the Willdan Group 2008 Performance Incentive Plan, including a 380,000-share increase in available awards and extension of the plan term to 2036, materially affecting future dilution and executive compensation capacity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure reports the results of Elauwit Connection's annual meeting of stockholders held on June 18, 2026, including voting outcomes for three proposals: election of three directors (Leslie Goodman, David O'Brien, and Barry Rubens), ratification of WithumSmith+Brown, PC as independent auditor, and approval of an adjournment proposal. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, and broker non-votes) are the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-18
Item 1.01
Yorkville International Capital Corp. completed its initial public offering on June 17, 2026, issuing 23 million units at $10.00 per unit for $230 million in gross proceeds. The IPO involved entry into multiple material agreements including the Underwriting Agreement, Warrant Agreement, Investment Management Trust Agreement, and Registration Rights Agreement, representing a material capital-raising event and change of control for the blank-check company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Simultaneously with the IPO closing, Yorkville issued 6,300,000 unregistered warrants (4,000,000 to the Sponsor and 2,300,000 to CCM) at $1.00 per warrant pursuant to Section 4(a)(2) exemption, materially diluting existing and new shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-18
Item 5.02
Four new directors—Kevin McGurn, Owen A. May, Mark Hiltwein, and John-Paul Colaco—were appointed to the board in connection with the company's IPO on June 16, 2026, with assignments to various board committees.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 5.03
Yorkville filed amended and restated memorandum and articles of association in connection with its IPO, implementing corporate governance amendments required for the company's transition to a publicly traded blank-check SPAC.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
Zura Bio held its Annual Meeting of Shareholders on June 17, 2026, with voting results on four proposals: election of eight directors, ratification of WithumSmith+Brown, PC as independent auditor, approval of the Amended 2023 Equity Incentive Plan, and an adjournment proposal. Detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are disclosed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-18
Item 1.01
Ford Credit Auto Receivables Two LLC (the Depositor) entered into an Underwriting Agreement on June 16, 2026 for the issuance of asset-backed securities by Ford Credit Auto Owner Trust 2026-B, involving the disposition of auto receivables and securitization of those assets.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-18
EX-99.1
This press release announces final results from a Grade Control drilling program at Mayfair's Fenn-Gib Project, validating the mineral reserve model and confirming ore-grade material characteristics. The disclosure is material to investors as it de-risks the project by confirming reserve estimates, validates early-years high-grade feed availability, and supports project financing discussions—all critical milestones for a development-stage gold company advancing toward 2028 construction. However, it does not fit neatly into standard event categories (not earnings, M&A, impairment, or litigation), making it an operational/strategic milestone best classified as operational_other.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-18
Item 5.02
The filing discloses both a departure (Mitchell Arnold's separation as VP of Finance and Principal Accounting Officer) and an appointment (Robert Weinstein's appointment as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately). While both events occur on the same date, the appointment of Weinstein—a seasoned CFO with 30+ years of experience in healthcare finance—represents the principal forward-looking action and is emphasized in the disclosure structure. The appointment fills a critical financial leadership role and is material to investors assessing the company's financial oversight.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 3.03
FirstCash completed a reincorporation from Delaware to Texas on June 18, 2026, following stockholder approval at the June 9, 2026 Annual Meeting. The Company's governance shifted from Delaware law to Texas law with automatic 1:1 conversion of shares and new Texas Charter/Bylaws, though stockholders' economic rights remain substantially unchanged.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Stellus Private Credit BDC disclosed an unregistered sale of 330,687 common shares for $5,000,000 pursuant to Section 4(a)(2) and Regulation D, structured as capital drawdowns under subscription agreements with existing investors. This is a classic dilutive issuance of equity securities exempt from registration, material to investors assessing the company's capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-18
Item 8.01
This Item 8.01 disclosure concerns supplemental proxy statement disclosures in connection with a merger transaction. The filing explicitly references the Arrangement Agreement dated January 25, 2026 (amended May 15, 2026) whereby Goldgroup Merger Sub Inc. will merge with and into Gold Resource Corporation, with the Company surviving as a wholly owned subsidiary of Goldgroup. The Company is providing supplemental disclosures to address threatened shareholder litigation regarding proxy statement completeness. This is a material acquisition/change of control event, and the supplemental disclosures—including updated share counts, financial projections, and fairness opinion details—are integral to the merger disclosure obligations.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-18
Item 5.02
The filing discloses multiple compensatory arrangements approved by the Board on June 18, 2026: (1) an updated non-employee director compensation program with specified annual cash retainers; (2) a $5.0 million change-in-control Retention and Incentive Plan with annual CPI-U adjustments; (3) a performance-based Waterfall Merger Incentive Program tied to IRR thresholds; and (4) confirmation of vesting of 35,419 RSUs under the 2020 LTIP. These are material compensation arrangements that would affect investor assessment of executive incentives and retention structures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-18
Item 1.02
The filing discloses termination of a Business Combination Agreement (BCA) between Papaya Growth Opportunity Corp. I (a SPAC) and 2744026 Alberta Ltd., which constitutes a material change of control transaction. The Company issued a Notice of Termination on June 12, 2026, citing alleged breaches by the SPAC under Section 9.1(f)(i) of the BCA. Although the SPAC disputes the termination, the termination of a material definitive agreement governing a business combination is a core M&A event that would materially affect investor assessment of the registrant's prospects.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-18
EX-99.1
The exhibit discloses a material deconsolidation transaction completed on June 12, 2026, in which Glass House Brands separated its dual-use cannabis retail business (Glass House Retail, LLC) from its medical cannabis operations. The transaction fundamentally restructures the company's business by segregating two distinct operating segments, with pro-forma financial statements showing the impact on balance sheet and operations. This constitutes a material disposition/change of control event under Item 1.02 or 2.01 of Form 8-K equivalents.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-18
Item 6.02
The filing discloses Rocket Companies' acquisition of Mr. Cooper Group Inc. on October 1, 2025, which included Nationstar Mortgage LLC (the Master Servicer for this Trust). While Item 6.02 nominally addresses servicer changes, the underlying event is a material acquisition that resulted in a change of control of the servicer entity. The disclosure emphasizes the Merger and subsequent Internal Reorganization transferring the master servicing function to Rocket, making this fundamentally an M&A event affecting the Trust's servicer.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-18
Item 2.03
The Company entered into a Confidential Side Letter Agreement with Evergreen Capital Management creating a direct financial obligation to pay an aggregate Installment Amount of $1,417,164.99 in three monthly installments, plus an obligation to issue 100,000 equity shares. While this arises from a forbearance arrangement on existing debt rather than a new debt issuance per se, it creates a new direct financial obligation structured as a payment plan with specific due dates and amounts, which falls within Item 2.03's scope of "Creation of a Direct Financial Obligation." The materiality is evident from the substantial dollar amount and the equity consideration involved.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-06-18
Item 8.01
The filing discloses a declaration by the Board of Directors of a cash dividend of $0.26 per share payable on August 3, 2026, to shareholders of record as of July 20, 2026. This is a routine but material dividend distribution to equity holders, clearly fitting the dividend_distribution category.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This Item 5.07 disclosure presents the final voting results from AlTi Global's June 17, 2026 Annual Meeting of Stockholders, including tabulated votes for the election of seven directors and ratification of KPMG LLP as independent auditor. The detailed vote counts (For, Withhold/Against, Broker Non-Votes) for each proposal are the core content, matching the shareholder_vote_results event type precisely.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-18
Item 2.02
Grace Therapeutics issued a press release on June 18, 2026 announcing financial results for the fiscal year ended March 31, 2026, including net loss of $7.8 million, R&D expenses of $2.4 million, and cash position of $17.0 million. The filing is made pursuant to Item 2.02 "Results of Operations and Financial Condition" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. While the release also discusses regulatory developments (FDA Complete Response Letter and Type A meeting), the core disclosure is the fiscal year-end financial results.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 8.01
Grace Therapeutics disclosed an update to its corporate presentation on June 18, 2026, which includes material regulatory and clinical information about GTx-104. The presentation details the FDA's Complete Response Letter (CRL) received in April 2026 citing CMC and manufacturing deficiencies (not clinical deficiencies), a scheduled Type A meeting with the FDA, and comprehensive Phase 3 STRIVE-ON trial data showing clinical and pharmacoeconomic benefits over oral nimodipine. While the CRL itself represents a regulatory setback, the disclosure centers on updating investors with the company's regulatory pathway forward and clinical evidence supporting GTx-104's potential. This does not fit neatly into the more specific categories (not a restatement, going concern, impairment, or litigation), but the regulatory status and clinical trial results are material to investor assessment of the company's prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-18
Item 1.01
Viatris completed a public offering of €650 million in senior notes on June 17, 2026, designated for refinancing $1.675 billion of maturing 2026 Senior Notes. This material financing activity represents a significant capital structure event affecting the company's financial position and debt obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-18
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of PENN Entertainment's 2026 Annual Meeting of Shareholders held on June 16, 2026. The filing presents voting results for five matters: election of Class III directors (Marla Kaplowitz, Jane Scaccetti, Fabio Schiavolin, and Jay Snowden), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory vote on executive compensation, approval of the third amendment to the 2022 Long-Term Incentive Compensation Plan, and an advisory vote on annual director elections. All results are presented with vote counts for, against, abstentions, and broker non-votes, which is the standard format for shareholder vote result disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-18
Item 8.01
This Item 8.01 disclosure centers on a material acquisition—the proposed merger of NCR Atleos Corporation into Brink's Company via a two-step merger structure. The filing describes the Merger Agreement executed February 26, 2026, the SEC-declared effective registration statement (Form S-4), scheduled shareholder votes on June 30, 2026, and supplemental disclosures addressing litigation and disclosure claims. Although styled as "Other Events," the substance is M&A activity—a change of control transaction material to both parties' shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-18
Item 8.01
This Item 8.01 disclosure concerns the pending merger between Brink's Company and NCR Atleos Corporation, announced February 26, 2026, with shareholder votes scheduled for June 30, 2026. The filing addresses litigation challenging the merger and provides supplemental disclosures to the joint proxy statement/prospectus. While technically an "Other Events" item, the substance is material M&A activity—specifically, disclosure of litigation and supplemental information related to a major acquisition that would materially affect the registrant's future.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-18
Item 7.01
The disclosure announces that the Form S-4 registration statement for a business combination between PCSC and Freenome Holdings, Inc. was declared effective by the SEC on June 17, 2026. The filing explicitly states that "the parties anticipate that the Business Combination will close in July 2026" and describes a definitive business combination agreement dated December 5, 2025. This represents a material M&A activity—specifically the regulatory approval milestone in a merger transaction that will result in PCSC being renamed "Freenome, Inc." upon closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-18
Item 7.01
Tina Carew has been named Executive Vice President, Chief Legal Officer and Corporate Secretary of City First Bank, effective June 17, 2026. This is a clear executive appointment to a senior officer role with significant responsibilities for corporate governance, regulatory disclosure, and board advisory operations. The appointment of a named executive to a C-suite position is material to investors assessing the company's leadership and governance structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses a Sales Agreement with A.G.P./Alliance Global Partners authorizing an at-the-market (ATM) offering of up to $75 million in Class A common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, registered on Form S-3 and declared effective June 4, 2026. ATM offerings are material capital-raising events that dilute existing shareholders and signal the company's liquidity needs.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-18
EX-99.1
This press release discloses the results of Satellos' Annual Meeting of Shareholders held June 17, 2026, including voting results for the election of nine directors and re-appointment of PricewaterhouseCoopers LLP as auditors. The exhibit explicitly presents a detailed voting table showing votes for and against each director nominee, with all nominees elected. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material to investors as it confirms board composition and auditor retention.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-18
EX-99.1
The press release announces the appointment of Richard Pozzebon as Chief Financial Officer of Titan Mining Corporation, effective July 6, 2026. This is a clear executive appointment of a named officer to a C-suite position. The disclosure includes his extensive qualifications (23+ years finance experience, 15+ years in resource sector, prior CFO roles at Interfor, Hecla Mining, and Western Coal) and the CEO's statement about his expected contributions to strategic growth and capital allocation, making this material to investors assessing management quality and leadership continuity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-18
EX-99.1
This press release announces a development agreement between Cespira (Westport's joint venture with Volvo Group) and Volvo Group to finalize hydrogen-fueled engine development using Cespira's HPDI™ fuel system technology. The disclosure describes a material strategic partnership milestone—extending proven LNG technology to hydrogen applications with a targeted commercial launch before 2030—that would affect a reasonable investor's assessment of Westport's technology roadmap and market opportunities, but does not fit the specific categories of M&A activity, earnings, executive changes, or financial obligations.
View raw filing on EDGAR →